Carobbio, Alessandra
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 5.441
NA - Nord America 4.138
EU - Europa 1.733
SA - Sud America 694
AF - Africa 82
OC - Oceania 12
Continente sconosciuto - Info sul continente non disponibili 1
Totale 12.101
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.020
CN - Cina 2.230
SG - Singapore 1.368
BR - Brasile 527
HK - Hong Kong 515
VN - Vietnam 458
KR - Corea 425
IT - Italia 409
FI - Finlandia 298
GB - Regno Unito 297
RU - Federazione Russa 163
FR - Francia 131
SE - Svezia 124
BD - Bangladesh 121
AR - Argentina 84
ID - Indonesia 79
DE - Germania 63
IN - India 56
NL - Olanda 55
CA - Canada 49
LT - Lituania 43
MX - Messico 41
PK - Pakistan 37
JP - Giappone 30
ZA - Sudafrica 30
ES - Italia 23
IQ - Iraq 23
PL - Polonia 23
AT - Austria 22
EC - Ecuador 21
UA - Ucraina 20
CO - Colombia 18
MA - Marocco 12
CL - Cile 11
UZ - Uzbekistan 11
CZ - Repubblica Ceca 10
JM - Giamaica 10
PY - Paraguay 10
GR - Grecia 9
TN - Tunisia 9
CR - Costa Rica 8
NP - Nepal 8
AU - Australia 7
PE - Perù 7
TR - Turchia 7
ET - Etiopia 6
KE - Kenya 6
PH - Filippine 6
SA - Arabia Saudita 6
VE - Venezuela 6
HR - Croazia 5
JO - Giordania 5
MY - Malesia 5
UY - Uruguay 5
AZ - Azerbaigian 4
BA - Bosnia-Erzegovina 4
BG - Bulgaria 4
BO - Bolivia 4
CH - Svizzera 4
DZ - Algeria 4
EG - Egitto 4
GE - Georgia 4
IE - Irlanda 4
IL - Israele 4
KZ - Kazakistan 4
RO - Romania 4
SI - Slovenia 4
TW - Taiwan 4
AE - Emirati Arabi Uniti 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
KH - Cambogia 3
LB - Libano 3
NZ - Nuova Zelanda 3
OM - Oman 3
QA - Qatar 3
RS - Serbia 3
AM - Armenia 2
BH - Bahrain 2
HN - Honduras 2
NG - Nigeria 2
NO - Norvegia 2
SY - Repubblica araba siriana 2
TH - Thailandia 2
AO - Angola 1
BY - Bielorussia 1
CG - Congo 1
CI - Costa d'Avorio 1
DK - Danimarca 1
DM - Dominica 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
IR - Iran 1
LA - Repubblica Popolare Democratica del Laos 1
LR - Liberia 1
MD - Moldavia 1
MK - Macedonia 1
ML - Mali 1
Totale 12.087
Salva come PNG Salva come JPEG
Città #
Hefei 1.544
Santa Clara 1.308
Singapore 764
San Jose 551
Hong Kong 509
Ashburn 459
Seoul 423
Helsinki 283
London 239
Council Bluffs 222
Ho Chi Minh City 182
Chicago 107
The Dalles 107
Hanoi 95
Kent 90
Lauterbourg 90
Beijing 86
Milan 85
Los Angeles 84
Moscow 64
Jakarta 58
New York 51
Boardman 49
Buffalo 49
Salt Lake City 47
Redondo Beach 46
São Paulo 42
Shanghai 37
Amsterdam 29
Dallas 28
Brooklyn 25
Da Nang 25
Phoenix 24
Nuremberg 23
Rio de Janeiro 21
Rome 21
Elk Grove Village 20
Denver 18
Tokyo 18
Warsaw 17
Curitiba 16
Frankfurt am Main 16
Johannesburg 16
Tampa 16
Atlanta 15
Haiphong 15
Karachi 15
Miano 14
Ealing 13
Tianjin 13
Boston 12
Guangzhou 12
Brasília 11
Campinas 11
Chennai 11
Guayaquil 11
Lappeenranta 11
Vienna 11
Baghdad 10
Dhaka 10
Florence 10
Houston 10
Mexico City 10
Piscataway 10
Tashkent 10
Orem 9
Toronto 9
Assago 8
Biên Hòa 8
Chengdu 8
Dulles 8
Fort Lauderdale 8
Lahore 8
Miami 8
Montreal 8
Ninh Bình 8
Padua 8
Paris 8
Salvador 8
Wilmington 8
Bari 7
Buenos Aires 7
Cape Town 7
Hillsboro 7
Maceió 7
Porto Alegre 7
Seattle 7
Shenzhen 7
Sterling 7
Turin 7
Addis Ababa 6
Baton Rouge 6
Bogotá 6
Caxias do Sul 6
Falkenstein 6
Lancaster 6
Leander 6
Newark 6
Poplar 6
Quito 6
Totale 8.501
Salva come PNG Salva come JPEG
Nome #
Clonal Hematopoiesis in Myeloproliferative Neoplasms Confers a Predisposition to both Thrombosis and Cancer 187
Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial 177
Association between cuffed tracheal tube use and reduced ventilator-associated pneumonia and conditions after elective cardiac surgery in infants and young children 172
A pilot study of the Histone-Deacetylase inhibitor Givinostat in patients with JAK2V617F positive chronic myeloproliferative neoplasms 155
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes 154
A globally applicable “triple A” risk model for essential thrombocythemia based on Age, Absolute neutrophil count, and Absolute lymphocyte count 153
Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19 153
Acute and Subacute Outcome Predictors in Moderate and Severe Traumatic Brain Injury: A Retrospective Monocentric Study 151
Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis) 151
Long-term follow-up of recovered MPN patients with COVID-19 148
Masked polycythemia vera (mPV): results of an international study 147
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients 147
Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms 143
A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis: a study by the International Working Group on Myelofibrosis Research and Treatment 142
Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera 137
A short low-dose imatinib trial allows rapid identification of responsive patients in hypereosinophilic syndromes 136
A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis 136
Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study 133
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study 132
Adherence of ticagrelOr in real world patients with aCute coronary syndrome: The AD-HOC study 131
Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer. A case-control study 129
Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study 128
Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation 128
High rate of recurrent venous thromboembolism in patients with myeloproliferative neoplasms and effect of prophylaxis with vitamin K antagonists 128
Risk of thrombosis in patients with essential thrombocythemia and polycythemia vera according to JAK2 V617F mutation status 125
Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia 122
Induction of Remission With Exclusive Enteral Nutrition in Children With Crohn’s Disease: Determinants of Higher Adherence and Response 119
Clinical outcomes under hydroxyurea treatment in polycythemia vera: a systematic review and meta-analysis 119
Association between inhibitors of the renin-angiotensin system and lung function in elderly patients recovered from severe COVID-19 118
High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib 117
Risk factors for arterial and venous thrombosis in WHO-defined essential thrombocythemia: an international study of 891 patients 116
Human platelet lysate allows expansion and clinical grade production of mesenchymal stromal cells from small samples of bone marrow aspirates or marrow filter washouts 116
Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis 116
A lower intensity of treatment may underlie the increased risk of thrombosis in young patients with masked polycythaemia vera 114
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia 114
Ruxolitinib for the prevention of thrombosis in polycythemia vera: a systematic review and meta-analysis 114
JAK2V617F allele burden and thrombosis: a direct comparison in essential thrombocythemia and polycythemia vera 114
Are the available data sufficient to suggest cytoreductive agents for patients with CHIP and stroke? 113
ASXL1 mutations in primary and secondary myelofibrosis 113
Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera 113
Hydroxyurea in essential thrombocythemia: rate and clinical relevance of responses by European LeukemiaNet criteria 111
Initial bone marrow reticulin fibrosis in polycythemia vera exerts an impact on clinical outcome 111
Thrombosis in primary myelofibrosis: incidence and risk factors 111
Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia 110
Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin 109
No correlation of intensity of phlebotomy regimen with risk of thrombosis in polycythemia vera: evidence from European Collaboration on Low-Dose Aspirin in Polycythemia Vera and Cytoreductive Therapy in Polycythemia Vera clinical trials 108
Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study 108
Masked polycythemia vera diagnosed according to WHO and BCSH classification 106
The impact of a standardized perioperative management on hospital mortality after the Norwood procedure in a low volume center: results and perspectives 105
Increased risk of thrombosis in JAK2 V617F-positive patients with primary myelofibrosis and interaction of the mutation with the IPSS score 105
One-year mortality in COVID-19 is associated with patients’ comorbidities rather than pneumonia severity 103
Leukocytosis as an important risk factor for arterial thrombosis in WHO-defined early/prefibrotic myelofibrosis: an international study of 264 patients 103
Risk factors for intubation in severe bronchiolitis: a useful tool to decide on an early intensive respiratory support 102
Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID‐19 101
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status 101
Three-month mortality in permanently bedridden medical non-oncologic patients. The BECLAP study (permanently BEdridden, creatinine CLearance, albumin, previous hospital admissions study) 101
The status of PD-L1 and tumor-infiltrating immune cells predict resistance and poor prognosis in BRAFi-treated melanoma patients harboring mutant BRAFV600 100
Leukocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis 100
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 100
Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach 99
Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study 98
Splanchnic Vein Thromboses associated with Myeloproliferative Neoplasms: an international, retrospective study on 518 cases 97
Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial 97
Innovative haematological parameters for early diagnosis of sepsis in adult patients admitted in intensive care unit 97
Pre-Transplant Alpha-Fetoprotein > 25.5 and Its Dynamic on Waitlist Are Predictors of HCC Recurrence after Liver Transplantation for Patients Meeting Milan Criteria 97
Direct oral anticoagulants for myeloproliferative neoplasms: results from an international study on 442 patients 97
Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera 96
Generating signals of drug-adverse effects from prescription databases and application to the risk of arrhythmia associated with antibacterials 96
Echocardiographic outflow pump ramp test in centrifugal-flow left ventricular assist device 96
Impact of ruxolitinib on survival of patients with myelofibrosis in the real world: update of the ERNEST Study 95
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases 95
Full-right-full-left split liver transplantation: the retrospective analysis of an early multicenter experience including graft sharing 94
In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology 94
The effect of arterial hypertension on thrombosis in low-risk polycythemia vera 92
Patterns of presentation and thrombosis outcome in patients with polycythemia vera strictly defined by WHO-criteria and stratified by calendar period of diagnosis 92
Telomere shortening in Ph-negative chronic myeloproliferative neoplasms: a biological marker of polycythemia vera and myelofibrosis, regardless of hydroxycarbamide therapy 92
Second versus first wave of COVID-19 in patients with MPN 91
Predicting the occurrence of embolic events: an analysis of 1456 episodes of infective endocarditis from the Italian Study on Endocarditis (SEI) 91
Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early Ropeginterferon alfa-2b therapy 90
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis 90
Splanchnic vein thrombosis in myeloproliferative neoplasms: risk factors for recurrences in a cohort of 181 patients 89
Thrombosis in myeloproliferative neoplasms during cytoreductive and antithrombotic drug treatment 89
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classification 89
ACE inhibitors and cytoreductive therapy in polycythemia vera 89
Hydroxyurea prevents arterial and late venous thrombotic recurrences in patients with myeloproliferative neoplasms but fails in the splanchnic venous district. Pooled analysis of 1500 cases 88
Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: A systematic review 88
Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma 88
PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics 87
The histone deacetylase inhibitor ITF2357 selectively targets cells bearing mutated JAK2(V617F) 86
CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis 86
Outcome of patients activating an unrelated donor search: the impact of transplant with reduced intensity conditioning in a large cohort of consecutive high-risk patients 85
Second cancers in MPN : Survival analysis from an international study 85
Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria 84
The rate of transformation from JAK2-mutated ET to PV is influenced by an accurate WHO-defined clinico-morphological diagnosis 84
Leukocytosis and thrombosis in polycythemia vera: can clinical trials settle the debate? 82
Prediction models for essential thrombocythemia from two longitudinal studies involving 2000 patients 82
Disease characteristics and clinical outcome in young adults with essential thrombocythemia versus early/prefibrotic primary myelofibrosis 81
Discriminating between essential thrombocythemia and masked polycythemia vera in JAK2 mutated patients 81
Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis 80
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data 80
Totale 11.045
Salva come PNG Salva come JPEG
Categoria #
all - tutte 49.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 49.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/2024415 0 0 0 0 0 0 0 210 37 17 64 87
2024/20253.911 40 25 28 270 745 769 220 47 405 144 592 626
2025/20267.931 703 728 1.034 1.089 391 423 988 291 845 602 540 297
Totale 12.257